Twitter Logo Youtube Circle Icon LinkedIn Icon

France > Industry focus > Healthcare and life sciences > Law firm and leading lawyer rankings

Editorial

Index of tables

  1. Industry focus: healthcare and life sciences
  2. Other recommended firms
  3. Leading individuals

Leading individuals

  1. 1

The ‘excellent’ 16-lawyer team at Allen & Overy LLP is recommended for high-value pharmaceutical patent matters and has experience in cases seeking amendments to legislation. The firm acts for various pharmaceuticals laboratories – it is representing Novartis in a dispute with Teva and Biogaran regarding the enforcement of second medical use patents. GlaxoSmithKline and Pfizer are also clients. Practice head Laëtitia Bénard is ‘an advocate for bringing France to the forefront of modern pharmaceutical patent practice’. The ‘pragmatic and tenacious’ David Por is also recommended along with recently promoted partner Alexandre Rudoni.

Dechert has ‘unique healthcare and M&A expertise’, and the team ‘knows perfectly the pharmaceuticals business’. The practice advises a number of leading pharmaceuticals manufacturers and biotechnology groups in patent litigation and other matters. It assisted the French subsidiaries of GlaxoSmithKline during several strategic exchanges of assets with Novartis. Practice head Alain Decombe has ‘extremely good knowledge of the industry’. Also recommended are recently promoted partners Isabelle Marguet and Anne-Charlotte Rivière. Marianne Schaffner is a key name for patent litigation. The hiring of Mélanie Thill-Tayara from Norton Rose Fulbright augmented the firm’s range of experience in competition law.

Dentons shows an ‘excellent knowledge of the pharmaceuticals field’ and ‘provides a high-quality product in desired time’. The firm has one of the market’s most comprehensive practices, extending to having strong experience in corporate and regulatory matters for many of the world’s largest pharmaceuticals businesses. It assisted Laboratoires Servier Monde with the establishment of a strategic international partnership with GeNeuro. The practice is headed by Pascale Poupelin and Jean-Marc Grosperrin, who is praised for ‘his leadership and insightful legal guidance’. Olivia Guéguen is a ‘deal-maker who is able to manage expectations on both sides of the table’ and Anne-Laure Marcerou is also recommended.

Hogan Lovells (Paris) LLP stands out for its ability to manage ‘very high-value mass tort claims’. It is defending TÜV Rheinland AG in sensitive litigation resulting from the certification of French breast implant PIP. Other clients include Eli Lilly and Sanofi Pasteur MSD. Practice head Cécile Derycke is ‘an excellent strategist and a refined and persistent courtroom lawyer’. The firm also assists leading laboratories with patent matters through Stanislas Roux-Vaillard, while the ‘technically excellent’ Mikael Salmela deals with regulatory work.

Sea Avocats, which now fields three lawyers following the hiring of the highly experienced Alain Gorny from LexCase, has ‘a perfect mastery of healthcare law’ and is involved in highly sensitive product liability cases. It also has strong regulatory expertise. Pierre Fabre Médicament, Sanofi Pasteur MSD and Medtronic are clients.

Simmons & Simmons LLP stands out for its comprehensive range of expertise and its leading product liability practice. The firm advises the world’s largest laboratories and is handling several of France’s most high-profile product liability cases; regulatory and tax issues are other areas of expertise. GlaxoSmithKline and Merck & Co are clients. Jacques-Antoine Robert heads the firm’s international life sciences group. Other key figures in the practice are Alexandre Regniault, Etienne Kowalski, Jean-Luc Cuadrado and of counsel Eric Nigri. Michèle Anahory joined DLA Piper.

CMS has leading regulatory expertise and recently challenged governmental orders regarding product classifications and reimbursement. Expanscience and Negma are clients. Practice head Bernard Geneste is recommended.

De Gaulle Fleurance & Associés fields ‘excellent’ lawyers that ‘remain focused on their clients’ objectives’. The team assists manufacturers of medical devices, pharmaceuticals and biotech products. The regulatory and patent practice is particularly strong, while product liability is another active area. Transactional work included assisting Takara Bio with the acquisition of Cellectis AB. Key figures in the team include Jean-Marie Job, who is one of the market’s top regulatory experts, Louis de Gaulle and Valérie Lafarge-Sarkozy. The practice hired Blandine Fauran.

Fieldfisher has ‘excellent knowledge of the healthcare sector’. The six-lawyer team assists leading generics laboratories and medical devices manufacturers with litigation, regulatory and distribution matters. It recently handled challenging work regarding the wholesale of drugs in France. Practice head Olivier Lantrès is ‘responsive and technical’. Brigitte Daille-Duclos is another key figure.

HBC Avocats has ‘strong expertise in biotechnology’ and ranks among the best for negotiating licensing and research agreements. Genticel and Genethon are clients. The three-lawyer team recently assisted Valneva with the negotiation of an exclusive licensing agreement for vaccine production in China. Practice head Jonathan Burnham has ‘in-depth knowledge of the French, UK and US legal framework’.

Intuity utilises its regulatory, litigious and competition expertise in representing leading laboratories and medical devices companies. The practice has been involved in product liability cases concerning Parkinson’s disease treatments and contraceptive pills. Christophe Hénin and Anne Servoir are strongly recommended.

McDermott Will & Emery AARPI advises leading pharmaceuticals groups on strategic transactions, such as acting for Servier on its exclusive licensing agreement with Taiho Pharmaceutical of Japan. The firm also advises biotech companies. Practice head Emmanuelle Trombe is strongly recommended. Anthony Paronneau was promoted to partner.

Reed Smith is ‘very helpful in terms of navigating the French legal system and explaining it to American clients’. The firm advises leading laboratories, medical devices manufacturers and private clinics. It has leading IP and patent litigation expertise through Marina Cousté and François Jonquères, as well as solid regulatory experience. The ‘fantastic’ Daniel Kadar ‘breaches the cultural divide’, while Benoît Charot and Marie Albertini are recommended for litigation.

Viguié Schmidt’s Etienne Gouesse assists leading laboratories in sensitive product liability cases and also handles regulatory work.

Winston & Strawn LLP has ‘remarkable knowledge of the healthcare sector’ and ‘ranks among the best firms for M&A work in the field’. The ten-lawyer team is ‘able to innovate in a very complex and highly regulated environment’, and has helped to modernise the French healthcare industry by developing new corporate structures. Générale de Santé is a client. Practice head Gilles Bigotranks among the best in France in terms of technique, knowledge and innovation’. Anne-Carine Ropars-Furet, Guillaume-Denis Faure and of counsel Florence Naudin are also recommended.

Interview with...

Law firm partners and practice heads explain how their firms are adapting to clients' changing needs

International comparative guides

Giving the in-house community greater insight to the law and regulations in different jurisdictions.

Select Practice Area

GC Powerlist -
Europe

Press releases

The latest news direct from law firms. If you would like to submit press releases for your firm, send an email request to

Legal Developments in France

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to
  • The new French regulation applying to national insurance contributions for managers and shareholders

    French insurance contributions on executive and shareholder remuneration (pay + dividends) have been substantially increased by the National Insurance Funding for 2013 Act, No. 2012-1404, of 17th December 2012. Until 31st December 2012, all dividends were subject to national insurance contributions on unearned income but henceforth, under Article L136-3 of the National Insurance Code, amended by Act No. 2012-1404, certain dividends   are considered as pay received by executives and shareholders and are therefore subject to the national insurance contributions on pay. The Act also abolished the ceiling on health insurance contributions payable by the self-employed and all this means that businesses must rethink the way that they have been structured until now.
  • CHINA - PERSONAL TAXATION AND SOCIAL SECURITY : CHINESE AND FOREIGN NATIONALS ON AN EQUAL FOOTING

    The People's Republic of China has initiated an overhaul of its social security system, reformed the personal taxation regime and has extended the scope of these laws to foreigners residing in China.
  • MOROCCO TO BECOME THE LEADING FINANCIAL PLACE IN AFRICA

    The Kingdom of Morocco is supporting the ambition of becoming the leading financial place for Africa. In this context, a wave of draft laws is to be passed and implemented within the following months, amongst which, the Law No. 53.08, setting up a new financial authority, and the Law No. 54.08, reforming public offering rules, are of paramount importance to Moroccan and foreign issuers, and financial institutions.
  • ACQUISITIONS IN CHINA : ASSET OR SHARE DEAL?

    The opportunities offered to foreign investors by the Chinese mergers and acquisitions market are increasing every year: in 2010, transactions involving foreign companies came to 60.1 billion euros, an increase of 21.2% compared with 2009. Seen from the West, where markets are declining, all sectors of the Chinese economy seem to be undergoing promising development and the statistics indicate that the Middle Empire will be a lasting springboard for growth.
  • Prime de Partage des Profits

    Le dispositif L’article 1er de la loi de financement rectificative de la Sécurité sociale pour 2011 oblige les sociétés commerciales de 50 salariés et plus, dont les dividendes par part sociale ou par action sont en augmentation par rapport à la moyenne des deux années précédentes, à verser une prime à l’ensemble de leurs salariés
  • BULGARIA MARKET OVERVIEW

    Types of investors The private equity (PE) funds that are active in Bulgaria are not raised or registered in the country. Some Bulgarian PE funds were raised recently, but there are no statistics as to the sources of their funding, their number, the funds that were accumulated, etc.
  • RECENT DEVELOPMENTS REGARDING COMMITMENTS

    THE PROCEDURE IS CLARIFIED, BUT MAY COMMITMENTS APPLY WITHOUT LIMIT?
  • Landmark decision by French Competition Authority in conditioned LPG case

    cartel case closed after discovery that leniency application was largely based on forgeries and rejection of collective dominant position objection.
  • 2012 supplementary budget

    The second supplementary budget published in the Official Gazette September 19, 2011 provides for two key measures that affect the deferral of tax losses and taxation of capital gains realized on the sale of equity securities .
  • Actualité législative fiscale

    Au delà des mesures applicables à l’ensemble des contribuables (telles que la limitation du report des déficits ou la réforme du mode de calcul des plus values sur cessions de participations),le plan de réduction des déficits annoncé le 24 août dernier par le gouvernement comprend des mesures qui intéressent spécifiquement les acteurs du secteur financier.

Press Releases worldwide

The latest news direct from law firms. If you would like to submit press releases for your firm, send an email request to